Enspryng has been approved by the Taiwan Food and Drug Administration for treating people 12 and older who have aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD), Chugai Pharmaceutical announced. The import drug license…
AQP4
Recent Posts
- With NMOSD, my to-do lists now include staying well, as well as staying busy
- Advocates join forces to create, celebrate World NMOSD Awareness Day
- With a compromised immune system, constant infections are my nemesis
- Approved NMOSD therapies better than rituximab at preventing relapses
- Embracing an opportunity for advocacy on Rare Disease Day